RASAZILECT rasagiline mesilate 1 mg tablets, blister

国: オーストラリア

言語: 英語

ソース: Department of Health (Therapeutic Goods Administration)

即購入

公開評価報告書 公開評価報告書 (PAR)
16-05-2019

有効成分:

rasagiline mesilate, Quantity: 1.56 mg

から入手可能:

Arrotex Pharmaceuticals Pty Ltd

医薬品形態:

Tablet, uncoated

構図:

Excipient Ingredients: purified talc; microcrystalline cellulose; maize starch; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid

投与経路:

Oral

パッケージ内のユニット:

10, 30

処方タイプ:

(S4) Prescription Only Medicine

適応症:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

製品概要:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

認証ステータス:

Registered

承認日:

2018-01-23